Selective serotonin reuptake inhibitor toxicity: Difference between revisions
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Most serious adverse effect is potential to produce [[serotonin | *Most serious adverse effect is potential to produce [[serotonin syndrome]] | ||
* | **However, serotonin syndrome unlikely to occur unless co-ingested with other serotonergic drug classes (MAOIs, SNRI, TCAs, amphetamines, opiates) | ||
* | *Pure overdoses are generally benign (mortality uncommon). Associated with less toxicity than tricyclic antidepressants. | ||
*Are the most commonly prescribed antidepressants in the United States<ref>Pirraglia PA, Stafford RS, Singer DE. Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care. Prim Care Companion J Clin Psychiatry. 2003 Aug;5(4):153-157. doi: 10.4088/pcc.v05n0402. PMID: 15213776; PMCID: PMC419384.</ref> | |||
*Examples include fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), sertraline (Zoloft), escitalopram (Lexapro), and citalopram (Celexa) | *Examples include fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), sertraline (Zoloft), escitalopram (Lexapro), and citalopram (Celexa) | ||
*Citalopram (>600 mg) and escitalopram (>300mg) are unique, as they may cause dose dependent [[QT prolongation]] and increase risk of [[torsades de pointes]] | |||
*Citalopram (>600 mg) and escitalopram (>300mg) are unique, as they may cause dose dependent QT prolongation and increase risk of torsades de pointes | |||
==Clinical Features== | ==Clinical Features== | ||
Revision as of 21:17, 6 July 2022
Background
- Most serious adverse effect is potential to produce serotonin syndrome
- However, serotonin syndrome unlikely to occur unless co-ingested with other serotonergic drug classes (MAOIs, SNRI, TCAs, amphetamines, opiates)
- Pure overdoses are generally benign (mortality uncommon). Associated with less toxicity than tricyclic antidepressants.
- Are the most commonly prescribed antidepressants in the United States[1]
- Examples include fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), sertraline (Zoloft), escitalopram (Lexapro), and citalopram (Celexa)
- Citalopram (>600 mg) and escitalopram (>300mg) are unique, as they may cause dose dependent QT prolongation and increase risk of torsades de pointes
Clinical Features
- Symptoms
- Signs
- Altered mental status
- Autonomic instability
- Diaphoresis
- Hyperthermia
- Hypertension/hypotension
- Neuromuscular hyperactivity
- Hyperreflexia
- Muscular rigidity
- Resting tremor
- Sinus tachycardia
- QRS, QT prolongation (citalopram only)
Differential Diagnosis
- Serotonin syndrome
- Neuroleptic Malignant Syndrome
- Acetaminophen Toxicity
- Withdrawal Syndromes
- Encephalitis
- Heatstroke
- Hyperthyroidism
- Meningitis
- Rhabdomyolysis
- Tetanus
Anticholinergic toxicity Causes
- Medications[2]
- Atropine
- Antihistamines
- Antidepressants
- Antipsychotics
- Muscle relaxants
- Anti-Parkinsonians
- Plants
- Jimson weed (Devil's trumpet)
- Amanita mushroom
Evaluation
Workup
Diagnosis
Management
- Supportive care
- No role for activated charcoal or gastric lavage
- Magnesium sulfate 2g IV if QTc > 500 msec
- IV benzodiazepines if agitation or seizures
- Treatment is mostly supportive. Consult poison control for guidance
- Administer activated charcoal if lethal amount ingested within 1-2 hours
- Continuous cardiac monitoring required for citalopram (>600 mg) and escitalopram (>300mg) for at least 8 hours. If citalopram (>1000 mg) and escitalopram (>500 mg) has been ingested then monitor for 12-24 hours
- Manage seizures w/ benzodiazepines
- Manage hyperthermia
- If suspecting Serotonin Syndrome, stop all serotonergic medication:
- SSRIs
- Anticonvulsants (valproate)
- Antiemetics (ondansetron, metoclopramide)
- Analgesics (fentanyl, tramadol, methadone)
- Antibiotics (linezolid)
Disposition
- Consider admission for patients who are tachycardic or lethargic 6hr after ingestion
- ECG before clearing a patient with citalopram ingestion
See Also
External Links
References
- ↑ Pirraglia PA, Stafford RS, Singer DE. Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care. Prim Care Companion J Clin Psychiatry. 2003 Aug;5(4):153-157. doi: 10.4088/pcc.v05n0402. PMID: 15213776; PMCID: PMC419384.
- ↑ Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2015;81(3):516-24.